semaglutide and bowel obstruction Semaglutide-Induced Small Pseudo-Obstruction Ileitis in a Patient With Type 2 Diabetes: A Case Report Ozempic Bowel Obstruction Ileus Lawsuit

Preventative care

This collaborative approach ensures infection control and GLP-1 efficacy without unnecessary risk

A Beginner's Guide to Metabolic & Hormonal Health 7 Types of Therapeutic Peptides and What Each One Does for Your Body GLP-1 Peptides Explained: How Semaglutide and Tirzepatide Are Reshaping Metabolic Medicine Peptide Therapy and Mainstream Medicine in 2026: The Evidence How to Verify Peptide Therapy Safety: Red Flags, COA Checks, and a Provider Checklist Research Peptides vs Pharmaceutical Grade: Why the Difference Could Harm You FDA July 2026 Peptide Meeting: What Patients Need to Know 8 Reasons to Get Lab Work Before Starting Any Weight Loss Program Medical Disclaimer: This article is written for educational purposes

Clinical Safety Screens Performed MTC personal AND family history in the comorbidity multi-select MEN-2 personal AND family history separately Substance / opioid screen with three-month opiate window + free-text dose, frequency, dates Suicidality and recent suicide attempt as exclusionary opt-out Active cancer treatment and cancer-free-for-five-years exclusionary End-stage kidney and liver disease opt-out Severe GI screen (gastroparesis, blockage, IBD) Pancreatitis history in the multi-select Self-reported blood pressure range and resting heart rate Past 2-month GLP-1 use (semaglutide / tirzepatide / none) No validated PHQ-2 or PHQ-9 depression instrument suicidality is captured as a binary exclusionary opt-out and severe depression is a checkbox on the comorbidity multi-select, but the validated brief screening scale is not used

If the liver cannot process both medications effectively, it may lead to liver damage